Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Guy

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
The Journal of Infectious Diseases|February 13, 2008
Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoesCharles E McGee, Konstantin Tsetsarkin, Dana L Vanlandingham, et al.
Vaccine|May 1, 2018
Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopesValerie Lecouturier, Catherine Berry, Aure Saulnier, et al.
Journal of Travel Medicine|October 17, 2019
Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infectionMatthew Bonaparte, Lingyi Zheng, Sanjay Garg, et al.
Expert Review of Vaccines|June 8, 2017
A recombinant live attenuated tetravalent vaccine for the prevention of dengueBruno Guy, Fernando Noriega, R Leon Ochiai, et al.
The Journal of Infectious Diseases|February 13, 2008
Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primatesCharles E McGee, Mark G Lewis, Marisa St Claire, et al.
Human Vaccines & Immunotherapeutics|June 10, 2017
Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccinationClaire Vigne, Martin Dupuy, Aline Richetin, et al.
Vaccine|April 25, 2006
Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)Violette Sanchez, Sophie Gimenez, Brian Tomlinson, et al.
Clinical and Vaccine Immunology : CVI|March 24, 2012
Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine developmentNoëlle Mistretta, Bruno Guy, Yves Bérard, et al.
Vaccine|November 27, 2002
Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pyloriStavros Sougioultzis, Cynthia K Lee, Mazen Alsahli, et al.
The Journal of Infectious Diseases|December 10, 2016
Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed IndividualsSandra Henein, Jesica Swanstrom, Anthony M Byers, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
The Journal of Infectious Diseases|February 13, 2008
Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoesCharles E McGee, Konstantin Tsetsarkin, Dana L Vanlandingham, et al.
Vaccine|May 1, 2018
Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopesValerie Lecouturier, Catherine Berry, Aure Saulnier, et al.
Journal of Travel Medicine|October 17, 2019
Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infectionMatthew Bonaparte, Lingyi Zheng, Sanjay Garg, et al.
Expert Review of Vaccines|June 8, 2017
A recombinant live attenuated tetravalent vaccine for the prevention of dengueBruno Guy, Fernando Noriega, R Leon Ochiai, et al.
The Journal of Infectious Diseases|February 13, 2008
Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primatesCharles E McGee, Mark G Lewis, Marisa St Claire, et al.
Human Vaccines & Immunotherapeutics|June 10, 2017
Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccinationClaire Vigne, Martin Dupuy, Aline Richetin, et al.
Vaccine|April 25, 2006
Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)Violette Sanchez, Sophie Gimenez, Brian Tomlinson, et al.
Clinical and Vaccine Immunology : CVI|March 24, 2012
Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine developmentNoëlle Mistretta, Bruno Guy, Yves Bérard, et al.
Vaccine|November 27, 2002
Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pyloriStavros Sougioultzis, Cynthia K Lee, Mazen Alsahli, et al.
The Journal of Infectious Diseases|December 10, 2016
Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed IndividualsSandra Henein, Jesica Swanstrom, Anthony M Byers, et al.
Pageof 6